Free Trial
NYSE:PRME

Prime Medicine (PRME) Stock Price, News & Analysis

$5.30
-0.27 (-4.84%)
(As of 07/19/2024 ET)
Today's Range
$5.25
$5.60
50-Day Range
$5.08
$8.03
52-Week Range
$4.11
$15.75
Volume
489,793 shs
Average Volume
1.01 million shs
Market Capitalization
$636.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.09

Prime Medicine MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
184.5% Upside
$15.09 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.77mentions of Prime Medicine in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.64) to ($1.47) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.55 out of 5 stars

Medical Sector

264th out of 896 stocks

Biological Products, Except Diagnostic Industry

34th out of 151 stocks

PRME stock logo

About Prime Medicine Stock (NYSE:PRME)

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

PRME Stock Price History

PRME Stock News Headlines

Prime Medicine (NYSE:PRME) Shares Gap Up to $5.78
We’re in a code red crisis and 99% of Americans are clueless
Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES!
We’re in a code red crisis and 99% of Americans are clueless
Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES!
Prime Medicine, Inc. (PRME)
See More Headlines
Receive PRME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/10/2024
Today
7/21/2024
Next Earnings (Estimated)
8/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Fax
N/A
Employees
234
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.09
High Stock Price Target
$20.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+184.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$-198,130,000.00
Pretax Margin
-34,592.21%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.37 per share

Miscellaneous

Free Float
90,875,000
Market Cap
$636.76 million
Optionable
Optionable
Beta
2.25
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Keith Michael Gottesdiener Ph.D. (Age 70)
    President, CEO, Secretary & Director
    Comp: $924.04k
  • Dr. Ann L. Lee Ph.D. (Age 62)
    Chief Technical Officer
    Comp: $947.28k
  • Mr. Richard Brudnick (Age 66)
    Chief Business Officer
    Comp: $680.8k
  • Dr. Andrew Anzalone M.D. (Age 37)
    Ph.D., Co-Founder & Head of Prime Editing Platform
  • Dr. David R. Liu Ph.D.
    Co-Founder & Chair of Scientific Advisory Board
  • Dr. Allan Reine M.D. (Age 49)
    Chief Financial Officer
  • Dr. Meredith Goldwasser (Age 52)
    Senior VP and Head of Strategy & Corporate Operations
  • Ms. Carman Alenson CPA (Age 58)
    M.B.A., Senior VP of Finance & Chief Accounting Officer
  • Dr. Jeremy S. Duffield M.D. (Age 56)
    Ph.D., Chief Scientific Officer
    Comp: $994.4k
  • Dr. Karen Brown J.D.
    Ph.D., Senior Vice President of Intellectual Property & Legal Affairs

PRME Stock Analysis - Frequently Asked Questions

How have PRME shares performed this year?

Prime Medicine's stock was trading at $8.86 on January 1st, 2024. Since then, PRME stock has decreased by 40.1% and is now trading at $5.3050.
View the best growth stocks for 2024 here
.

How were Prime Medicine's earnings last quarter?

Prime Medicine, Inc. (NYSE:PRME) posted its quarterly earnings results on Friday, May, 10th. The company reported ($0.44) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.01. The firm had revenue of $0.59 million for the quarter.

When did Prime Medicine IPO?

Prime Medicine (PRME) raised $175 million in an initial public offering on Thursday, October 20th 2022. The company issued 10,294,118 shares at a price of $16.00-$18.00 per share.

Who are Prime Medicine's major shareholders?

Top institutional shareholders of Prime Medicine include Sumitomo Mitsui Trust Holdings Inc. (2.70%), Nisa Investment Advisors LLC (0.01%) and ORG Partners LLC. Insiders that own company stock include Robert Nelsen and 2019 Gp LLC Gv.
View institutional ownership trends
.

How do I buy shares of Prime Medicine?

Shares of PRME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:PRME) was last updated on 7/21/2024 by MarketBeat.com Staff

From Our Partners